Medicine and Dentistry
Breast Cancer
100%
Metastatic Breast Cancer
29%
Disease
21%
Neoplasm
20%
Triple Negative Breast Cancer
19%
Immunotherapy
15%
Clinical Trial
15%
Recurrent Disease
14%
Patient-Reported Outcome
13%
Hormone Receptor
11%
Hormone Therapy
11%
Pembrolizumab
10%
Brain Metastasis
10%
Malignant Neoplasm
10%
Symptom
10%
Immunocompetent Cell
9%
Aromatase Inhibitor
8%
Gamma Urogastrone
8%
Capecitabine
7%
Medical Oncology
7%
Epidermal Growth Factor Receptor 2
7%
Receptor
7%
Tumor Microenvironment
7%
Radiation Therapy
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Niraparib
6%
Neoadjuvant Chemotherapy
6%
BRCA1
6%
COVID-19
6%
Overall Survival
6%
Metastatic Carcinoma
5%
Arm
5%
Programmed Death-Ligand 1
5%
Biological Marker
5%
Neoadjuvant Therapy
5%
Body Mass Index
5%
Progression Free Survival
5%
Keyphrases
Breast Cancer
48%
Triple-negative Breast Cancer
26%
Metastatic Breast Cancer
25%
Early Breast Cancer
22%
Chemotherapy
17%
Breast Cancer Patients
14%
Pembrolizumab
12%
HER2-positive
11%
Clinical Trials
10%
Pathological Complete Response
10%
Phase II Study
10%
Endocrine Therapy
10%
Tumor Microenvironment
9%
Breast Cancer Survivors
9%
Tumor
8%
Neoadjuvant
8%
Hormone Receptor-positive
8%
Carboplatin
7%
Trastuzumab
7%
Metastatic Triple-negative Breast Cancer
7%
Atezolizumab
6%
Patients with Breast Cancer
6%
Brain Metastases
6%
Circulating Tumor DNA (ctDNA)
6%
Developmental Therapeutics
6%
Longitudinal Assessment
6%
Intensive Longitudinal Data
6%
Circulating Immune Cells
6%
Radiation Therapy
6%
Neoadjuvant Chemotherapy
6%
Spatial Landscape
6%
Capecitabine
6%
Physical Symptoms
6%
Aromatase Inhibitors
6%
Immune Checkpoint Inhibitors
6%
Quantitative Systems Pharmacology
5%
Recurrence Risk
5%
BRCA1, BRCA2
5%
Patient-reported Outcomes
5%
Human Epidermal Growth Factor Receptor 2 (HER2)
5%
Overweight or Obesity
5%
Light Physical Activity
5%
Breast Cancer Recurrence
5%
Moderate-to-vigorous Physical Activity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
39%
Neoplasm
23%
Triple Negative Breast Cancer
19%
Metastatic Breast Cancer
14%
Immunotherapy
12%
Recurrent Disease
12%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
Disease
9%
Malignant Neoplasm
9%
Biological Marker
8%
Clinical Trial
8%
Chemotherapy
8%
Aromatase Inhibitor
7%
Atezolizumab
6%
Brain Metastasis
6%
Endocrine Therapy
6%
Trastuzumab
6%
Receptor
6%
Solid Malignant Neoplasm
6%
Carboplatin
6%
Tumor Microenvironment
5%
